SCHEMBL23974677

SCHEMBL23974677

CC(=O)N1CCC(NCCC2CCC(c3ncccc3C)CC2)CC1

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 16/20 0.71
TRPV1 Q8NER1 1/20 0.48
LTA4H P09960 1/20 0.42
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23974457 0.89 OPRL1 (0.68) OPRL1
SCHEMBL23974363 0.86 OPRL1 (0.78) OPRL1
SCHEMBL23974567 0.83 OPRL1 (1.00) OPRL1
SCHEMBL30127788 0.83 OPRL1 (1.00) OPRL1
SCHEMBL23974337 0.82 OPRL1 (1.00) OPRL1
SCHEMBL23974613 0.80 OPRL1 (1.00) OPRL1
SCHEMBL23974612 0.80 OPRL1 (1.00) OPRL1
SCHEMBL23974671 0.80 OPRL1 (1.00) OPRL1
SCHEMBL23974658 0.79 OPRL1 (0.67) OPRL1
SCHEMBL30127857 0.75 OPRL1 (1.00) OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144411-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE LLC 2023-05-11 US disclosed
US-20230144411-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE LLC 2023-05-11 US disclosed
EP-3759085-B1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE LLC (US) 2022-12-14 EP disclosed
US-11365191-B2 Substituted cyclohexyl compounds as NOP inhibiiors DART NEUROSCIENCE, LLC (US) 2022-06-21 US disclosed
US-20210340127-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE, LLC 2021-11-04 US disclosed
CN-112105605-A Substituted cyclohexyl compounds as NOP inhibitors 达特神经科学有限公司 2020-12-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340127-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS OPRL1, OPRK1, NOP56 OPRL1 1/4885TRPV1 1609/4885LTA4H 4471/4885
US-11365191-B2 Substituted cyclohexyl compounds as NOP inhibiiors OPRL1, OPRK1, GAP43 OPRL1 1/4885TRPV1 1177/4885LTA4H 4599/4885
US-20230144411-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS OPRL1, OPRK1, NOP56 OPRL1 1/4885TRPV1 1609/4885LTA4H 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.